Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.

Biotechnology

Adaptive Phage Therapeutics

Joseph Fackler

Rob Casper

Jacqueline Rivera

Carl R. Merril

Eric Zirkle

Emae Lee-Voritskul, CPA

Edward Fang

The leadership team of Adaptive Phage Therapeutics has a long and varied history in both the public and private sectors when it comes to scientific research and development. Members of the team have worked with renowned organizations such as the National Institutes of Health, Hibiscus Bioventures, LLC, and ATRIN PHARMACEUTICALS. They also bring a wealth of experience in areas such as financial reporting, auditing, and product development. Furthermore, the team is well-educated, with members holding degrees from respected institutions such as William & Mary, the University of Maryland, and the University of Maryland School of Medicine.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Adaptive Phage Therapeutics

Board of Directors

CEO and Executive Team